Quoin Pharmaceuticals (QNRX) investor relations material

Executive summary

• Focused on developing therapies for rare and orphan diseases, with QRX003 in late-stage clinical trials for Netherton Syndrome and expansion into other indications and geographies.

• Achieved significant regulatory milestones for QRX003, including FDA Fast Track Designation and Orphan Drug Designation eligibility in Japan, and filed for Breakthrough Medicine Designation in Saudi Arabia.

• On track to complete Phase 3 patient recruitment for QRX003 by end of 2026, with potential NDA filing in 2027.

• Advanced QRX009 topical rapamycin platform, with multiple investigator-led studies planned for rare dermatological indications.

• No products have been commercialized and no revenue generated to date; operations are funded by equity and debt financings.

Financial highlights

• Net loss for Q1 2026 was $5.0 million, compared to $3.8 million in Q1 2025, driven by higher R&D and G&A expenses.

• Cash, cash equivalents, and marketable securities totaled $14 million as of March 31, 2026.

• Accumulated deficit reached $76.0 million as of March 31, 2026.

• Operating expenses increased to $5.1 million in Q1 2026 from $4.0 million in Q1 2025, primarily due to a 44.7% rise in R&D spending.

• No revenue recognized in the quarter; all income derived from interest on investments.

Outlook and guidance

• Current cash position expected to fund operations into 2027.

• Management has concluded there is substantial doubt about the ability to continue as a going concern for at least one year without additional funding.

• Plans to seek further funding through equity, debt, or strategic partnerships; failure to secure capital may force reduction or cessation of operations.

• Topline data from QRX003 Phase 3 trial anticipated in the second half of 2026.

• No expectation of product revenue until successful completion and approval of clinical programs, which will take several years.